Johnson & Johnson (0R34)
LSE
Closed
Oct 5, 2026
Day's Range
252.8752 wk Range
180.27Overview - 0R34 - Johnson & Johnson
Key Statistics
Valuation
Enterprise Value
28.22B
P/E (Trailing)
‪24.28‬
PEG Ratio
‪-212.44‬
Price / Book
‪7.66‬
EV / EBITDA
‪0.80‬
Profitability
Gross Margin
‪68.19%‬
Profit Margin
‪67.87%‬
Operating Margin
‪35.62%‬
Return on Assets
‪13.45%‬
Return on Equity
‪32.87%‬
Ownership
Shares Outstanding
2.40B
Price stats
50-Day Avg
‪265.58‬
200-Day Avg
‪241.60‬
Dividends
Frequency
Quarterly
Peers - 0R34 - Johnson & Johnson
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on LSE.
- 0R34LSEJohnson & Johnson+33.37%52-week change24.29P/E (Trailing)‪67.87%‬Profit Margin
- SANLSESantander UK Plc Preferred Stock 10.375% Perpetual+98.91%52-week change0.38P/E (Trailing)‪19.73%‬Profit Margin
- 0QAHLSEMerck & Co., Inc.+46.92%52-week change63.23P/E (Trailing)‪5.33%‬Profit Margin
- 0P6SLSEBayer AG+44.73%52-week change19.01P/E (Trailing)‪-6.17%‬Profit Margin
- OGNLSEOrigin Enterprises plc+98.92%52-week change10.07P/E (Trailing)‪2.20%‬Profit Margin
- BAYLSEBay Capital Plc+99.66%52-week change-2608.70P/E (Trailing)‪0.00%‬Profit Margin
- 0R1BLSEBiogen Inc.+39.19%52-week change—P/E (Trailing)‪8.32%‬Profit Margin
Profile Summary - 0R34 - Johnson & Johnson
About
Johnson & Johnson is a multinational healthcare company focused on Innovative Medicine and MedTech. Johnson & Johnson develops prescription medicines across areas such as immunology, oncology, neuroscience, cardiopulmonary disease, infectious disease, and metabolic disorders, while its MedTech business provides…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
